Fadini Gian Paolo, Ferraro Francesca, Quaini Federico, Asahara Takayuki, Madeddu Paolo
Department of Medicine, University of Padova, Padova, Italy; Venetian Institute of Molecular Medicine, Padova, Italy; Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA; Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; Division of Regenerative Medicine, Department of Basic Clinical Science, Tokai University, Tokyo, Japan; Regenerative Medicine Section, Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
Department of Medicine, University of Padova, Padova, Italy; Venetian Institute of Molecular Medicine, Padova, Italy; Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA; Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; Division of Regenerative Medicine, Department of Basic Clinical Science, Tokai University, Tokyo, Japan; Regenerative Medicine Section, Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.
Stem Cells Transl Med. 2014 Aug;3(8):949-57. doi: 10.5966/sctm.2014-0052. Epub 2014 Jun 18.
Diabetes mellitus is a global health problem that results in multiorgan complications leading to high morbidity and mortality. Until recently, the effects of diabetes and hyperglycemia on the bone marrow microenvironment-a site where multiple organ systems converge and communicate-have been underappreciated. However, several new studies in mice, rats, and humans reveal that diabetes leads to multiple bone marrow microenvironmental defects, such as small vessel disease (microangiopathy), nerve terminal pauperization (neuropathy), and impaired stem cell mobilization (mobilopathy). The discovery that diabetes involves bone marrow-derived progenitors implicated in maintaining cardiovascular homeostasis has been proposed as a bridging mechanism between micro- and macroangiopathy in distant organs. Herein, we review the physiological and molecular bone marrow abnormalities associated with diabetes and discuss how bone marrow dysfunction represents a potential root for the development of the multiorgan failure characteristic of advanced diabetes. The notion of diabetes as a bone marrow and stem cell disease opens new avenues for therapeutic interventions ultimately aimed at improving the outcome of diabetic patients.
糖尿病是一个全球性的健康问题,会导致多器官并发症,进而引发高发病率和高死亡率。直到最近,糖尿病和高血糖对骨髓微环境(多个器官系统汇聚和交流的场所)的影响一直未得到充分认识。然而,几项针对小鼠、大鼠和人类的新研究表明,糖尿病会导致多种骨髓微环境缺陷,如小血管疾病(微血管病变)、神经末梢减少(神经病变)和干细胞动员受损(动员病)。糖尿病涉及参与维持心血管稳态的骨髓来源祖细胞这一发现,被认为是远处器官微血管病变和大血管病变之间的一种桥梁机制。在此,我们综述与糖尿病相关的生理和分子骨髓异常,并讨论骨髓功能障碍如何成为晚期糖尿病多器官衰竭发展的潜在根源。将糖尿病视为骨髓和干细胞疾病这一观念为最终旨在改善糖尿病患者预后的治疗干预开辟了新途径。